NCT04301011 - Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 2, 2020

Primary Completion Date

January 23, 2023

Study Completion Date

January 23, 2023

Conditions

Solid TumorMicrosatellite Stable Colorectal CancerHPV Positive Oropharyngeal Squamous Cell CarcinomaCervical CancerMelanoma (Skin)Cutaneous Squamous Cell CarcinomaMesotheliomaRenal Cell CarcinomaOropharynx Cancer

Interventions

BIOLOGICAL

TBio-6517

Engineered Oncolytic Vaccinia Virus

BIOLOGICAL

Pembrolizumab

Immune checkpoint inhibitor.

Trial Locations (11)

10408

National Cancer Center, Ilsandong

31031

The Billings Clinic, Billings

32224

Mayo Clinic, Jacksonville

33136

Sylvester Comprehensive Cancer Center / UMHC, Miami

55902

Mayo Clinic, Rochester

66205

University of Kansas Medical Center, Kansas City

77030

University of Texas MD Anderson Cancer Center, Houston

85054

Mayo Clinic, Phoenix

02215

Clinical Site 1007, Boston

Unknown

Ottawa Hospital and Research Institute (OHRI), Ottawa

03080

Seoul National University Hospital (SNUH), Junggu